These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 27102293)

  • 1. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.
    Boeckx N; Peeters M; Van Camp G; Pauwels P; Op de Beeck K; Deschoolmeester V
    Drugs; 2015 Oct; 75(15):1739-56. PubMed ID: 26347132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer.
    Dimou A; Syrigos K; Saif MW
    Anticancer Drugs; 2011 Jun; 22(5):384-91. PubMed ID: 21285867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
    Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
    ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
    Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA
    Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Abundance of KRAS and RAS Gene Mutations in Cancer.
    Stites EC
    Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Label-free and high-sensitive detection of Kirsten rat sarcoma viral oncogene homolog and epidermal growth factor receptor mutation using Kelvin probe force microscopy.
    Jang K; Choi J; Park C; Na S
    Biosens Bioelectron; 2017 Jan; 87():222-228. PubMed ID: 27566395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
    Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melting curve analysis for mutations of EGFR and KRAS.
    Furugaki K; Yasuno H; Iwai T; Moriya Y; Harada N; Fujimoto-Ouchi K
    Anticancer Res; 2014 Feb; 34(2):613-21. PubMed ID: 24510990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.